All In Biotech

Drug Trial Radar · NCT06340048

Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure

Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Ischemic Heart Failure

Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Sep 5, 2023

Primary completion

Nov 10, 2026

Study completion May 10, 2027

Sponsor

Lead sponsor
HELP Therapeutics Co., Ltd.Industry
Sponsor type
Industry
Collaborators
TEDA International Cardiovascular Hospital
First posted
Apr 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting (CABG) surgery in patients with severe chronic ischemic heart failure.

Conditions

  • Heart Failure

Interventions

  • HiCM-188 therapyDrug

    Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of major Serious Adverse Events (SAE)Time frame: Within the first month after surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • TEDA International Cardiovascular Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.